Post-Approval Requirements for Drugs: An Introduction to Safety Reporting and Post-Approval Changes

Understand regulatory requirements for post-approval safety reporting

  • Explain FDA’s drug safety activities
  • Describe the regulatory framework for post approval changes and supplemental New Drug Applications (NDAs) and Abbreviated NDAs (ANDAs)
  • Understand at a high-level:
    • Grounds for Withdrawal of Approval
    • Medicare, Medicaid and Reimbursement Issues
    • Drug Supply Chain Security Act (DSCSA) Product Tracing Requirements

David L. Rosen, Partner, Foley & Lardner LLP

This session was recorded as part of FDLI’s Introduction to Drug Law and Regulation Course in April 2022. 

Get Access

  • +$100 for nonmembers


Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.


Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content